相关实验视频
Updated: Jun 28, 2025

12:24
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
Published on: June 3, 2014
12.3K
因素XI:结构,功能和治疗抑制
Ahmed E Ali1, Richard C Becker2
1Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
Journal of thrombosis and thrombolysis
|April 15, 2024
概括
XI因子 (FXI) 抑制剂代表了一种有前途的新型抗凝剂类别,与现有疗法相比,可以通过降低出血风险提供更好的安全性. 目前正在进行广泛的临床试验,以确认它们在预防血栓形成方面的有效性和最佳使用.
科学领域:
- 心血管医学 心血管医学
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
背景情况:
- 血栓栓塞栓症仍然是一个重大的全球健康负担,需要有效的抗凝血治疗.
- 目前的抗凝血剂 (肝素,VKA,DOAC) 携带出血风险,推动寻找更安全的替代品.
- 本质凝血途径,特别是XI因子 (FXI),是新型抗凝血剂的有希望的目标,其安全性可能会得到改善.
研究的目的:
- 审查开发FXI抑制剂作为更安全的抗凝固剂的理由.
- 介绍目前正在开发中的先进的FXI抑制剂.
- 总结临床试验数据和FXI抑制剂的持续研究.
主要方法:
- 关于FXI缺乏和抑制的临床前研究和流行病学数据的审查.
- 分析了2期临床试验的结果,涉及各种指示 (骨科手术,心房动,ESRD,MI,中风).
- 评估各种FXI向策略,包括寡核酸,抗体,小分子,和体.
主要成果:
- 临床前和流行病学数据表明,FXI抑制可以降低出血风险并提供抗血栓保护.
- 第二阶段研究表明,FXI抑制剂在各种临床环境中具有有希望的疗效.
- 多种FXI抑制剂处于临床开发的各个阶段,证明了可行性.
结论:
- 与传统疗法相比,FXI 抑制剂是一种潜在的更安全的抗凝剂策略.
- 通过大规模的第三期试验进行进一步验证至关重要,以建立有效性和安全性之间的最佳平衡.
- 目前正在进行的研究和计划中的试验旨在确定FXI抑制剂在各种血栓状况中的临床作用和最佳应用.
相关概念视频
Anticoagulant Drugs: Low-Molecular-Weight Heparins
689
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
689
Clot Retraction and Fibrinolysis
5.7K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
5.7K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Extrinsic and Intrinsic Pathways of Hemostasis
7.4K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.4K
Structure and Function of Platelets
1.1K
The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...
1.1K
Coagulation
6.4K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.4K

